Gestational Diabetes May Signal Future Risk

04.06.20131913
Women with gestational diabetes who have a cluster of symptoms typical of metabolic syndrome are more likely to go on to develop diabetes over 10 years, researchers found.

Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial

03.06.20131940
Mineralocorticoid receptor antagonists (MRAs) improve outcomes in patients with heart failure and reduced left ventricular ejection fraction (HFrEF), but their use is limited by hyperkalaemia and/or worsening renal function (WRF).

Risk of incident diabetes among patients treated with statins: population based study

31.05.20132057
To examine the risk of new onset diabetes among patients treated with different HMG-CoA reductase inhibitors (statins).

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

30.05.20132066
The vascular and gastrointestinal effects of non-steroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors (coxibs) and traditional non-steroidal anti-inflammatory drugs (tNSAIDs), are not well characterised, particularly in patients at increased risk of vascular disease.

AAN: Don't Stop Warfarin for Dental Visits

29.05.20131997
Patients taking aspirin or warfarin (Coumadin) for prevention after a stroke don't need to stop the drug for dental procedures and probably can stay on it for most other minor medical procedures, the American Academy of Neurology recommended.

Rivaroxaban Gains Approval In Europe For ACS Indication

28.05.20131959
Rivaroxaban (Xarelto, Bayer ) has been approved in Europe for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) following an acute coronary syndrome (ACS).

Tumor Marker Carbohydrate Antigen 125 Predicts Adverse Outcome After Transcatheter Aortic Valve Implantation

27.05.20132125
What is the predictive value of tumor marker carbohydrate antigen 125 (CA125) before and after transcatheter aortic valve implantation (TAVI) for all-cause death and a composite endpoint of death, admission for heart failure, myocardial infarction, and stroke (major adverse cardiac events [MACE])?
Данный сайт и вся информация на нём предназначена для медицинских работников. Продолжая просмотр, вы соглашаетесь и подтверждаете, что являетесь медицинским работником.